- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05226000
Pharmacokinetics of Benaglutide Injection in Overweight/Obese Adults
This study is a open and multiple dose escalation phase I clinical study, aiming to evaluate the pharmacokinetic characteristics and safety of Benaglutide Injection in overweight/obese adults after multiple subcutaneous injections.
This study will enroll 16 overweight/obese adults, both male and female. The trial was divided into two batches, including 4 subjects who completed all dosing, safety assessment and telephone follow-up, and the remaining 12 subjects who were enrolled for the trial. All subjects received multiple doses (tid) of 0.06 mg, 0.1 mg, 0.14 mg, and 0.2 mg in sequence, followed by the next dose after completing the previous multiple dosing. The administration time of each dose was 0.06 mg for 3 days, 0.1 mg for 3 days, 0.14 mg for 5 days, and 0.2 mg for 5 days.
Subjects will be screened at D-14-D-2, and eligible subjects D-2 will be admitted to the phase I clinical trial ward at D-2. D-1 Blank blood samples were collected at different time points before and after breakfast for PK test baseline correction. D1 began by subcutaneously injecting different doses of benaglutide injection 5 minutes before the daily three meals, collecting biological samples at different time points after the first administration of D6, D7, D11, D12 and D16 to evaluate the pharmacokinetic characteristics of Benaglutide. Subjects will be discharged after all samples are collected and safety assessed at D17. Telephone follow-up was performed on the 7th day after discharge (D24±2) to further observe safety.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
Shandong
-
Qingdao, Shandong, Cina, 266003
- The Affiliated Hospital of Qingdao University
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Male or female aged between 18 and 70 years old (including the critical value).
BMI meets the following requirements (a or b):
- BMI>28 kg/m2;
- BMI>24 kg/m2 with at least one of the following symptoms:
Vigorous appetite, hunger before meals unbearable, each meal into more food. Combined with hyperglycemia, hypertension, dyslipidemia, fatty liver in one or several.
Combined with weight-bearing joint pain. Obesity causes dyspnea or obstructive sleep apnea syndrome.
- The following examination show that the indicators are normal or abnormal without clinical significance. The examination including: Vital signs, physical examination, blood routine, blood biochemistry, urinalysis, pregnancy test for female, serological tests for hepatitis B virus, hepatitis C virus, human immunodeficiency virus (HIV), and syphilis virus, 12 lead ECG.
- The subjects have no family planning within 3 months and could select contraceptive method.
- Before the study, all subjects have been informed of the study's purpose, protocal, benefits, and risks, and signed the informed consent voluntarily.
Exclusion Criteria:
- Patients with type 1 diabetes or type 2 diabetes with a clear diagnosis;
- Fasting intravenous blood glucose ≥7 mmol/L or 75g during screening. Oral glucose tolerance test (OGTT) two hours after glucose load;
- Fasting venous blood glucose <2.8 mmol/L at screening, and/or those with a history of hypoglycemia;
- Those who complained of a weight change of >5% within 3 months before screening;
- Have used weight loss drugs or hypoglycemic drugs that may affect body weight within 4 weeks before screening;
- Drugs used within 4 weeks before screening that may cause significant weight gain: including systemic glucocorticoid therapy (lasting more than 1 week); tricyclic antidepressants; antipsychotic or antidepressant drugs; may interfere with blood sugar regulation Functional medicine; all proprietary Chinese medicines and Chinese herbal medicines;
- Those who have a clear history of malignant tumors,
- People with Cushing's syndrome, hypothyroidism, polycystic ovary disease or other genetic endocrine diseases or medical history;
- Those who have a history of bariatric surgery;
- Have a history of multiple endocrine tumors or a family history; have a history of medullary thyroid carcinoma or other tumors, a family history;
- History of acute and chronic pancreatitis;
- Moderate to severe gastrointestinal diseases with additional gastrointestinal motility disorders or obstructive enteropathy;
- Have a clear history of mental illness
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Benaglutide Injection
All subjects received multiple doses (tid) of 0.06 mg, 0.1 mg, 0.14 mg, and 0.2 mg in sequence, followed by the next dose after completing the previous multiple dosing.
The administration time of each dose was 0.06 mg for 3 days, 0.1 mg for 3 days, 0.14 mg for 5 days, and 0.2 mg for 5 days.
|
All subjects received multiple doses (tid) of 0.06 mg, 0.1 mg, 0.14 mg, and 0.2 mg in sequence, followed by the next dose after completing the previous multiple dosing.
The administration time of each dose was 0.06 mg for 3 days, 0.1 mg for 3 days, 0.14 mg for 5 days, and 0.2 mg for 5 days.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Area sotto la curva della concentrazione plasmatica in funzione del tempo (AUC)0-t
Lasso di tempo: 80 giorni
|
Valutazione dell'area sotto la curva della concentrazione plasmatica in funzione del tempo (AUC)0-t
|
80 giorni
|
Peak Plasma Concentration (Cmax)
Lasso di tempo: 80 days
|
Evaluation of Peak Plasma Concentration (Cmax)
|
80 days
|
Area under the plasma concentration versus time curve (AUC)0-∞
Lasso di tempo: 80 days
|
Evaluation of Area under the plasma concentration versus time curve (AUC)0-∞
|
80 days
|
elimination half-life time(T1/2)
Lasso di tempo: 80 days
|
Evaluation of elimination half-life time(T1/2)
|
80 days
|
The total clearance(CL)
Lasso di tempo: 80 days
|
Evaluation of the total clearance(CL)
|
80 days
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Incidence of Treatment Adverse Events
Lasso di tempo: 80 days
|
Collection of adverse events
|
80 days
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- RH-RCT-IS-002
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Adulti in sovrappeso/obesi
-
Cumhuriyet UniversityCompletatoFatica | Addestramento | Donne obeseTacchino
-
Taipei City HospitalNational Yang Ming UniversitySconosciuto
-
Clinical Nutrition Research Center, Illinois Institute...CompletatoDonne in premenopausa | Donne in sovrappeso e obeseStati Uniti
-
Sabrin Mohamed Taha AbdelwahabCompletatoDonne obese con PCOSEgitto
-
Mackay Medical CollegeCompletatoDonne incinte in sovrappeso e obeseTaiwan
-
University Hospital, Clermont-FerrandSconosciuto
-
Universitas PadjadjaranCompletato
-
Hospital Clinic of BarcelonaTerminato
-
Assiut UniversityTerminatoMetformina per donne incinte obeseEgitto
-
Institut Pasteur de LilleLuxomedTerminatoValutare l'effetto di una riflessoterapia IR su persone in sovrappeso e obese di classe IFrancia
Prove cliniche su Benaglutide Injection
-
Changhai HospitalNon ancora reclutamentoLinfoma a cellule B recidivato o refrattario
-
Ruijin HospitalReclutamentoLinfoma a cellule B recidivato o refrattarioCina
-
Shanghai Junshi Bioscience Co., Ltd.CompletatoCarcinoma polmonare non a piccole cellule avanzato naïve al trattamentoCina
-
Bio-Thera SolutionsCompletato
-
Eye & ENT Hospital of Fudan UniversityChanghai Hospital; Shanghai Zhongshan Hospital; Fujian Medical University Union... e altri collaboratoriReclutamentoCarcinoma rinofaringeo ricorrenteCina
-
Beijing Biostar Pharmaceuticals Co., Ltd.Reclutamento
-
Hallym University Medical CenterReclutamento
-
SCRI Development Innovations, LLCIpsenTerminatoNeoplasie gastrointestinali | Tumori neuroendocrini | Tumori carcinoidiStati Uniti
-
Chiasma, Inc.CompletatoAcromegaliaStati Uniti, Spagna, Ungheria, Francia, Regno Unito, Austria, Germania, Italia, Lituania, Polonia, Romania, Federazione Russa, Serbia
-
Eicos Sciences, Inc.CompletatoFenomeno di Raynaud secondario alla sclerosi sistemicaStati Uniti